Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$85 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
28.32
EV/EBITDA
-2.5
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$--
EPS
$-3.6
Face value
--
Shares outstanding
61,386,300
CFO
$-371.71 Mln
EBITDA
$-393.99 Mln
Net Profit
$-370.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pliant Therapeutics Inc (PLRX)
| -89.7 | -0.7 | -11.7 | -88.5 | -41.7 | -44.4 | -- |
|
BSE Sensex*
| 4.3 | -0.9 | 10.5 | 6.0 | 16.6 | 19.4 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Pliant Therapeutics Inc (PLRX)
| -27.1 | -6.3 | 43.2 | -40.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pliant Therapeutics Inc (PLRX)
|
1.4 | 84.7 | 0.0 | -219.5 | -- | -72.8 | -- | 0.3 |
| 20.4 | 4,968.1 | 459.4 | 206.8 | 25.6 | 68.3 | 24.8 | 13.3 | |
| 29.8 | 3,780.7 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.8 | |
| 101.7 | 5,125.5 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 96.3 | |
| 56.2 | 10,781.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.8 | 1.9 | |
| 41.1 | 7,553.5 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 70.9 | 7,429.5 | 685.5 | 132.9 | 15.6 | 20.1 | 60.9 | 10.9 | |
| 14.0 | 6,858.7 | 4,427.0 | 373.0 | -0.7 | 5.8 | 18.4 | 1.1 | |
| 83.7 | 4,149.4 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.6 | 2.3 | |
| 9.0 | 10,469.2 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual... selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Read more
President, CEO & Director
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
President, CEO & Director
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Pliant Therapeutics Inc (PLRX) stood at $ 373 Mln as on 31-Mar-25
The share price of Pliant Therapeutics Inc (PLRX) is $1.36 (NASDAQ) as of 16-Jun-2025 16:00 EDT. Pliant Therapeutics Inc (PLRX) has given a return of -41.72% in the last 3 years.
Pliant Therapeutics Inc (PLRX) has a market capitalisation of $ 85 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Pliant Therapeutics Inc (PLRX) is 0.33 times as on 13-Jun-2025, a 93% discount to its peers’ median range of 4.84 times.
Since, TTM earnings of Pliant Therapeutics Inc (PLRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pliant Therapeutics Inc (PLRX) and enter the required number of quantities and click on buy to purchase the shares of Pliant Therapeutics Inc (PLRX).
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
The CEO & director of Dr. Bernard Coulie M.B.A., M.D., Ph.D.. is Pliant Therapeutics Inc (PLRX), and CFO & Sr. VP is Dr. Bernard Coulie M.B.A., M.D., Ph.D..
There is no promoter pledging in Pliant Therapeutics Inc (PLRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,096
|
|
|
1,054
|
|
|
755
|
|
|
741
|
|
|
709
|
|
|
532
|
|
|
522
|
|
|
421
|
|
|
386
|
| Pliant Therapeutics Inc (PLRX) | Ratios |
|---|---|
|
Return on equity(%)
|
-72.81
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Pliant Therapeutics Inc (PLRX) was $0 Mln.
$-0.02
(
